Innovation
Adam Koppel rejoined Bain Capital in 2016 as Managing Director of the Bain Capital Life Sciences Fund. He had initially joined Bain Capital Public Equity in 2003 where he was a leader
within the healthcare sector until mid-2014. During the period mid-2014 to mid-2016, Dr. Koppel was at Biogen where he served as EVP of Corporate Development and Chief Strategy Officer.
He sits on the Board of Directors of PTC Therapeutics (NASD: PTCT) and Trevena (NASD:TRVN). Prior to initially joining Bain Capital in 2003, Dr. Koppel was an Associate Principal at McKinsey
& Co in New Jersey where he served a variety of healthcare companies. Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with a AB and AM in History and Science.
